Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Most men who are treated for prostate cancer according to modern guidelines have good survival rates and the majority of ...

Kairos Pharma reports positive results from phase 2 trial of ENV-105 in advanced prostate cancer: Los Angeles Thursday, July 17, 2025, 15:00 Hrs [IST] Kairos Pharma, Ltd., a clini ...